DOCSLIB.ORG

Respiratory System Drug Poster

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Respiratory System Drug Poster Respiratory System Drugs Created by the Njardarson Group (The University of Arizona): Edon Vitaku, Elizabeth A. Ilardi, Monica A. Fallon, Erik B. Gerlach, Jack Siqueiros, Jón T. Njarðarson Codeine Cocaine Morphine Anästhesin Theophylline Aminophyllin Hycodan Hydrocodone Benadryl Dolophine Bacitracin Decapryn Xylocaine PBZ Chlor-Trimeton Neothylline Sus-Phrine Epinephrine Phenergen ( Codeine ) ( Cocaine ) ( Morphine ) ( Benzocaine ) ( Theophylline ) ( Aminophylline ) ( Homatropine & Hydrocodone ) ( Hydrocodone ) ( Diphenhydramine ) ( Methadone ) ( Bacitracin ) ( Doxylamine ) ( Lidocaine ) ( Tripelennamine ) ( Chlorpheniramine ) ( Dyphylline ) ( Epinephrine ) ( Epinephrine ) ( Promethazine ) COUGH & COLD PREP THROAT PREP COUGH & COLD PREP THROAT PREP OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES COUGH & COLD PREP COUGH & COLD PREP ANTIHISTAMINE COUGH & COLD PREP THROAT PREP ANTIHISTAMINE THROAT PREP ANTIHISTAMINE ANTIHISTAMINE OBSTRUCTIVE AIRWAY DISEASES NASAL PREP OBSTRUCTIVE AIRWAY DISEASES ANTIHISTAMINE Approved 1889 Approved 1896 (UK) Approved 1900s Approved 1902 (GER) Approved 1922 Approved 1940 Approved 1943 Approved 1943 Approved 1946 Approved 1947 Approved 1948 Approved 1948 Approved 1948 Approved 1948 Approved 1950 Approved 1951 Approved 1951 Approved 1951 Approved 1951 Promethazine/Cod Phenergan Vc/Cod Guaifenesin Phenylephr/Promethaz Multifuge Meticortelone Dimetane Promethaz/Dextromet Aristocort Aristocort Tessalon Decadron Triprolidine Phenylpropanolamine Soframycin Celestone Celestone Periactin Torecan ( Codeine & Promethazine ) ( Codeine, Phenylephrine & Promethazine ) ( Guaifenesin ) ( Phenylephrine & Promethazine ) ( Piperazine ) ( Prednisolone ) ( Brompheniramine ) ( Dextromethorphan & Promethazine ) ( Triamcinolone ) ( Triamcinolone ) ( Benzonatate ) ( Dexamethasone ) ( Triprolidine ) ( Phenylpropanolamine ) ( Framycetin ) ( Betamethasone ) ( Betamethasone ) ( Cyproheptadine ) ( Thiethylperazine ) ANTIHISTAMINE ANTIHISTAMINE COUGH & COLD PREP NASAL PREP OBSTRUCTIVE AIRWAY DISEASES NASAL PREP ANTIHISTAMINE COUGH & COLD PREP NASAL PREP OBSTRUCTIVE AIRWAY DISEASES COUGH & COLD PREP NASAL PREP ANTIHISTAMINE NASAL PREP NASAL PREP NASAL PREP OBSTRUCTIVE AIRWAY DISEASES ANTIHISTAMINE ANTIHISTAMINE Approved 1952 Approved 1952 Approved 1952 Approved 1954 Approved 1954 Approved 1955 Approved 1957 Approved 1957 Approved 1957 Approved 1957 Approved 1958 Approved 1958 Approved 1958 Approved 1959 Approved 1960s Approved 1961 Approved 1961 Approved 1961 Approved 1961 Disophrol Neomycin Sulfate Marezine Dopram Dyclone Disomer Bricanyl Diafen Rifamate Novafed Vanceril Vanceril Hibiclens Optimine Tavist Tacaryl Buclizine Delsym Trimeprazine ( Dexbrompheniramine & Pseudoephedrine ) ( Neomycin ) ( Cyclizine ) ( Doxapram ) ( Dyclonine ) ( Dexbrompheniramine ) ( Terbutaline ) ( Diphenylpyraline ) ( Isoniazid & Rifampin ) ( Pseudoephedrine ) ( Beclomethasone ) ( Beclomethasone ) ( Chlorhexidine ) ( Azatadine ) ( Clemastine ) ( Methdilazine ) ( Buclizine ) ( Dextromethorphan ) ( Trimeprazine ) ANTIHISTAMINE THROAT PREP ANTIHISTAMINE OTHER RESPIR. SYSTEM PRODS THROAT PREP ANTIHISTAMINE OBSTRUCTIVE AIRWAY DISEASES ANTIHISTAMINE OTHER RESPIR. SYSTEM PRODS NASAL PREP NASAL PREP OBSTRUCTIVE AIRWAY DISEASES THROAT PREP ANTIHISTAMINE ANTIHISTAMINE ANTIHISTAMINE ANTIHISTAMINE COUGH & COLD PREP ANTIHISTAMINE Approved 1963 Approved 1964 Approved 1965 Approved 1965 Approved 1970s Approved 1972 Approved 1974 Approved 1975 Approved 1975 Approved 1975 Approved 1976 Approved 1976 Approved 1976 Approved 1977 Approved 1977 Approved 1978 Approved 1979 Approved 1982 Approved 1982 Corphed Tornalate Triacin-C Aerobid Aerobid Mequitazine Bromfed-DM Seldane Aphthasol Atrovent Atrovent Ocuclear Bromodiphenhydramine Elocon Elocon Bactroban Astemizole Tilade Tilade ( Pseudoephedrine & Triprolidine ) ( Bitolterol ) ( Codeine, Pseudoephedrine & Triprolidine ) ( Flunisolide ) ( Flunisolide ) ( Mequitazine ) ( Brompheniramine, Dextromethorphan & Pseudoephedrine ) ( Terfenadine ) ( Amlexanox ) ( Ipratropium ) ( Ipratropium ) ( Oxymetazoline ) ( Bromodiphenhydramine ) ( Mometasone ) ( Mometasone ) ( Mupirocin ) ( Astemizole ) ( Nedocromil ) ( Nedocromil ) COUGH & COLD PREP OBSTRUCTIVE AIRWAY DISEASES ANTIHISTAMINE NASAL PREP OBSTRUCTIVE AIRWAY DISEASES ANTIHISTAMINE ANTIHISTAMINE ANTIHISTAMINE OBSTRUCTIVE AIRWAY DISEASES NASAL PREP OBSTRUCTIVE AIRWAY DISEASES NASAL PREP ANTIHISTAMINE NASAL PREP OBSTRUCTIVE AIRWAY DISEASES NASAL PREP ANTIHISTAMINE NASAL PREP OBSTRUCTIVE AIRWAY DISEASES Approved 1983 Approved 1984 Approved 1984 Approved 1984 Approved 1984 Approved 1984 Approved 1985 Approved 1985 Approved 1986 (JPN) Approved 1986 Approved 1986 Approved 1986 Approved 1987 Approved 1987 Approved 1987 Approved 1987 Approved 1988 Approved 1992 Approved 1992 Levostin Claritin Semprex-D Rhinocort Rifater Serevent Cedax Zyrtec Combivent Augmentin Astelin Tripedia Pulmozyme Allegra Flovent Flovent Visipaque Zosyn RespiGam ( Levocabastine ) ( Loratadine ) ( Acrivastine & Pseudoephedrine ) ( Budesonide ) ( Isoniazid, Pyrazinamide & Rifampin ) ( Salmeterol ) ( Ceftibuten ) ( Cetirizine ) ( Salbutamol & Ipratropium ) ( Amoxicillin & Clavulanate ) ( Azelastine ) ( Diptheria and Tetanus Toxoids & Acellular Pertussis Vaccine ) ( Dornase Alfa ) ( Fexofenadine ) ( Fluticasone ) ( Fluticasone Propionate ) ( Iodixanol ) ( Piperacillin & Tazobactam ) ( Respiratory Syncytial Virus Immune Globulin Intravenous ) NASAL PREP ANTIHISTAMINE NASAL PREP NASAL PREP OTHER RESPIR. SYSTEM PRODS OBSTRUCTIVE AIRWAY DISEASES COUGH & COLD PREP ANTIHISTAMINE OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES NASAL PREP OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES ANTIHISTAMINE OBSTRUCTIVE AIRWAY DISEASES NASAL PREP DIAGNOSTIC CONTRAST AGENT OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES Approved 1993 Approved 1993 Approved 1994 Approved 1994 Approved 1994 Approved 1994 Approved 1995 Approved 1995 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Approved 1996 Accolate Pulmicort Ceftin Cipro Allegra D 24 Hour Raxar Zagam TOBI Zyflo Infasurf Dynabac Singulair Synagis Curosurf Priftin Proventil HFA Tikosyn Tequin Zaditor ( Zafirlukast ) ( Budesonide ) ( Cefuroxime ) ( Ciprofloxacin ) ( Fexofenadine & Pseudoephedrine ) ( Grepafloxacin ) ( Sparfloxacin ) ( Tobramycin ) ( Zileuton ) ( Calfactant ) ( Dirithromycin ) ( Montelukast ) ( Palivizumab ) ( Poractant Alfa ) ( Rifapentine ) ( Salbutamol ) ( Dofetillide ) ( Gatifloxacin ) ( Ketotifen ) OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES OTHER RESPIR. SYSTEM PRODS ANTIHISTAMINE OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES OTHER RESPIR. SYSTEM PRODS OTHER RESPIR. SYSTEM PRODS OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES OTHER RESPIR. SYSTEM PRODS OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES OTHER RESPIR. SYSTEM PRODS OTHER RESPIR. SYSTEM PRODS ANTIHISTAMINE Approved 1996 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1997 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1998 Approved 1999 Approved 1999 Approved 1999 Approved 1999 INOmax Cefazolin & Dextrose Biaxin XL Advair HFA Azelastine NasalCrom Clarinex D 24 Hour Clarinex Invanz Foradil Avelox Xopenex Zemaira Carbinoxamine Elestat Iressa Xolair Mucinex DM Mucinex D ( Nitric Oxide ) ( Cefazolin & Dextrose ) ( Clarithromycin ) ( Fluticasone & Salmeterol ) ( Azelastine ) ( Cromoglicic Acid ) ( Desloratadine & Pseudoephedrine ) ( Desloratadine ) ( Ertapenam ) ( Formoterol ) ( Moxifloxacin ) ( Levosalbutamol ) ( Alpha-1-Proteinase ) ( Carbinoxamine ) ( Epinastine ) ( Gefitinib ) ( Omalizumab ) ( Dextromethorphan & Guaifenesin ) ( Pseudoephedrine & Guaifenesin ) OTHER RESPIR. SYSTEM PRODS OTHER RESPIR. SYSTEM PRODS OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES ANTIHISTAMINE NASAL PREP ANTIHISTAMINE ANTIHISTAMINE OTHER RESPIR. SYSTEM PRODS OBSTRUCTIVE AIRWAY DISEASES OTHER RESPIR. SYSTEM PRODS OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES ANTIHISTAMINE ANTIHISTAMINE OTHER RESPIR. SYSTEM PRODS OBSTRUCTIVE AIRWAY DISEASES COUGH & COLD PREP COUGH & COLD PREP Approved 1999 Approved 2000 Approved 2000 Approved 2000 Approved 2001 Approved 2001 Approved 2001 Approved 2001 Approved 2001 Approved 2001 Approved 2001 Approved 2002 Approved 2003 Approved 2003 Approved 2003 Approved 2003 Approved 2003 Approved 2004 Approved 2004 Ketek Spiriva HandiHaler Tygacil Brovana Symbicort Xyzal Alvesco Patanase Cayston Teflaro Dulera Xalkori Arcapta Daliresp Tudorza Dymista Sirturo Kalydeco Surfaxin ( Telithromycin ) ( Tiotropium ) ( Tigecycline ) ( Arformoterol ) ( Budesonide & Formoterol ) ( Levocetirizine ) ( Ciclesonide ) ( Olopatadine ) ( Aztreonam ) ( Ceftaroline ) ( Mometasone & Formoterol ) ( Crizotinib ) ( Indacaterol ) ( Roflumilast ) ( Aclidinium ) ( Azelastine & Fluticasone ) ( Bedaquilline ) ( Ivacaftor ) ( Sinapultide, DPPtdCho, POPG & Palmitic Acid ) OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES ANTIHISTAMINE OBSTRUCTIVE AIRWAY DISEASES ANTIHISTAMINE OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES OTHER RESPIR. SYSTEM PRODS OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES OBSTRUCTIVE AIRWAY DISEASES NASAL PREP OTHER RESPIR. SYSTEM PRODS OTHER RESPIR. SYSTEM PRODS OTHER RESPIR. SYSTEM PRODS Approved 2004 Approved 2004 Approved 2005 Approved 2006 Approved 2006 Approved 2007 Approved 2008 Approved 2008 Approved 2010 Approved 2010 Approved 2010 Approved 2011 Approved 2011 Approved 2011 Approved 2012 Approved 2012 Approved 2012 Approved 2012 Approved 2012 Abraxame Phenylephrine ( Paclitaxel ) ( Phenylephrine ) OTHER RESPIR. SYSTEM PRODS NASAL PREP Approved 2012 Approved 2012 All drugs are considered FDA approved in the U.S. following the passage of the Pure Food and Drugs Act in 1906. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ * Initially approved outsides of the U.S..
Load more

Recommended publications
  • Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers with Topical Pharmaceutical Agents
    Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents Author Watts, Annabelle M, Cripps, Allan W, West, Nicholas P, Cox, Amanda J Published 2019 Journal Title FRONTIERS IN PHARMACOLOGY Version Version of Record (VoR) DOI https://doi.org/10.3389/fphar.2019.00294 Copyright Statement © Frontiers in Pharmacology 2019. The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version. Downloaded from http://hdl.handle.net/10072/386246 Griffith Research Online https://research-repository.griffith.edu.au fphar-10-00294 March 27, 2019 Time: 17:52 # 1 REVIEW published: 29 March 2019 doi: 10.3389/fphar.2019.00294 Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents Annabelle M. Watts1*, Allan W. Cripps2, Nicholas P. West1 and Amanda J. Cox1 1 Menzies Health Institute Queensland, School of Medical Science, Griffith University, Southport, QLD, Australia, 2 Menzies Health Institute Queensland, School of Medicine, Griffith University, Southport, QLD, Australia Allergic rhinitis (AR) is a chronic upper respiratory disease estimated to affect between 10 and 40% of the worldwide population. The mechanisms underlying AR are highly complex and involve multiple immune cells, mediators, and cytokines. As such, the development of a single drug to treat allergic inflammation and/or symptoms is confounded by the complexity of the disease pathophysiology. Complete avoidance of allergens that trigger AR symptoms is not possible and without a cure, the available therapeutic options are typically focused on achieving symptomatic relief.
    [Show full text]
  • Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis
    Journal of Allergy Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis Guest Editors: Ralph Mösges, Carlos E. Baena-Cagnani, and Desiderio Passali Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis Journal of Allergy Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis Guest Editors: Ralph Mosges,¨ Carlos E. Baena-Cagnani, and Desiderio Passali Copyright © 2014 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “Journal of Allergy.” All articles are open access articles distributed under the Creative Commons At- tribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board William E. Berger, USA Alan P. Knutsen, USA Fabienne Ranc, France Kurt Blaser, Switzerland Marek L. Kowalski, Poland Anuradha Ray, USA Eugene R. Bleecker, USA Ting Fan Leung, Hong Kong Harald Renz, Germany JandeMonchy,TheNetherlands Clare M Lloyd, UK Nima Rezaei, Iran Frank Hoebers, The Netherlands Redwan Moqbel, Canada Robert P. Schleimer, USA StephenT.Holgate,UK Desiderio Passali, Italy Massimo Triggiani, Italy Sebastian L. Johnston, UK Stephen P. Peters, USA Hugo Van Bever, Singapore Young J. Juhn, USA David G. Proud, Canada Garry Walsh, United Kingdom Contents Nonpharmacological Treatment of Rhinoconjunctivitis and Rhinosinusitis,RalphMosges,¨ Carlos E. Baena-Cagnani, and Desiderio Passali Volume 2014, Article ID 416236, 2 pages Clinical Efficacy of a Spray Containing Hyaluronic Acid and Dexpanthenol after Surgery in the Nasal Cavity (Septoplasty, Simple Ethmoid Sinus Surgery, and Turbinate Surgery), Ina Gouteva, Kija Shah-Hosseini, and Peter Meiser Volume 2014, Article ID 635490, 10 pages The Effectiveness of Acupuncture Compared to Loratadine in Patients Allergic to House Dust ,Mites Bettina Hauswald, Christina Dill, Jurgen¨ Boxberger, Eberhard Kuhlisch, Thomas Zahnert, and Yury M.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • Amlexanox TBK1 & Ikke Inhibitor Catalog # Inh-Amx
    Amlexanox TBK1 & IKKe inhibitor Catalog # inh-amx For research use only Version # 15I29-MM PRODUCT INFORMATION METHODS Contents: Preparation of 10 mg/ml (33.5 mM) stock solution • 50 mg Amlexanox 1- Weigh 10 mg of Amlexanox Storage and stability: 2- Add 1 ml of DMSO to 10 mg Amlexanox. Mix by vortexing. - Amlexanox is provided lyophilized and shipped at room temperature. 3- Prepare further dilutions using endotoxin-free water. Store at -20 °C. Lyophilized Amlexanox is stable for at least 2 years when properly stored. Working concentration: 1-300 μg/ml for cell culture assays - Upon resuspension, prepare aliquots of Amlexanox and store at -20 °C. Resuspended Amlexanox is stable for 6 months when properly stored. TBK1/IKKe inhibition: Quality control: Amlexanox can be used to assess the role of TBK1/IKKe using cellular - Purity ≥97% (UHPLC) assays, as described below in B16-Blue™ ISG cells. - The inhibitory activity of this product has been validated using cellular 1- Prepare a B16-Blue™ ISG cell suspension at ~500,000 cells/ml. assays. 2- Add 160 µl of cell suspension (~75,000 cells) per well. - The absence of bacterial contamination (e.g. lipoproteins and 3- Add 20 µl of Amlexanox 30-300 µg/ml (final concentration) and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ incubate at 37 °C for 1 hour. TLR4 cells. 4-Add 20 µl of sample per well of a flat-bottom 96-well plate. Note: We recommend using a positive control such as 5’ppp-dsRNA delivered intracellularly with LyoVec™ . DESCRIPTION 5- Incubate the plate at 37 °C in a 5% CO incubator for 18-24 hours.
    [Show full text]
  • Rhinitis - Allergic (1 of 15)
    Rhinitis - Allergic (1 of 15) 1 Patient presents w/ signs & symptoms of rhinitis 2 • Consider other classifi cations of rhinitis DIAGNOSIS No - Please see Rhinitis Is allergic rhinitis - Nonallergic disease confi rmed? management chart Yes 3 ASSESS DURATION & SEVERITY OF ALLERGIC RHINITIS A Non-pharmacological therapy • Allergen avoidance • Patient education VAS <5 VAS ≥5 B Pharmacological therapy B Pharmacological therapy • Antihistamines (oral/nasal), &/or • Corticosteroids (nasal), w/ or without • Corticosteroids (nasal), or • Antihistamines (nasal), or • Cromone (nasal), or • LTRA • Leukotriene receptor antagonists (LTRA)MIMS TREATMENT © See next page Specifi cally for patients w/ asthma Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B167 © MIMS Pediatrics 2020 Rhinitis - Allergic (2 of 15) Previously treated symptomatic Previously treated symptomatic patient (VAS <5) on antihistamines patient (VAS ≥5) on intensifi ed (oral/nasal) &/or corticosteroids (nasal) therapy w/ corticosteroids (nasal) w/ or without antihistamines (nasal) Intermittent Persistent symptoms, symptoms or without allergen w/ allergen exposure exposure B Pharmacological therapy B Pharmacological therapy • Step down or discontinue therapy • Continue or step up therapy Untreated REASSESS DISEASE SEVERITY VAS symptomatic patient DAILY UP TO DAY 3 (VAS <5 or ≥5) 4 CONTINUE Yes THERAPY & STEP EVALUATION VAS <5 DOWN THERAPY1 Improvement of symptoms? No VAS ≥5 B Pharmacological therapy • Step-up therapy REASSESS DISEASE SEVERITY MIMSVAS DAILY UP TO DAY 7 4 Yes EVALUATION VAS <5 Improvement of symptoms? No TREATMENT © VAS ≥5 See next page Continue therapy if symptomatic; consider step-down or discontinuation of therapy if symptoms subside Not all products are available or approved for above use in all countries.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Fatty Liver Disease (Nafld/Nash)
    CAYMANCURRENTS ISSUE 31 | WINTER 2019 FATTY LIVER DISEASE (NAFLD/NASH) Targeting Insulin Resistance for the Metabolic Homeostasis Targets Treatment of NASH Page 6 Page 1 Special Feature Inside: Tools to Study NAFLD/NASH A guide to PPAR function and structure Page 3 Pathophysiology of NAFLD Infographic Oxidative Stress, Inflammation, and Apoptosis Targets Page 5 Page 11 1180 EAST ELLSWORTH ROAD · ANN ARBOR, MI 48108 · (800) 364-9897 · WWW.CAYMANCHEM.COM Targeting Insulin Resistance for the Treatment of NASH Kyle S. McCommis, Ph.D. Washington University School of Medicine, St. Louis, MO The obesity epidemic has resulted in a dramatic escalation Defects in fat secretion do not appear to be a driver of in the number of individuals with hepatic fat accumulation hepatic steatosis, as NAFLD subjects display greater VLDL or steatosis. When not combined with excessive alcohol secretion both basally and after “suppression” by insulin.5 consumption, the broad term for this spectrum of disease Fatty acid β-oxidation is decreased in animal models and is referred to as non-alcoholic fatty liver disease (NAFLD). humans with NAFLD/NASH.6-8 A significant proportion of individuals with simple steatosis will progress to the severe form of the disease known as ↑ Hyperinsulinemia Insulin resistance non-alcoholic steatohepatitis (NASH), involving hepatocyte Hyperglycemia damage, inflammation, and fibrosis. If left untreated, Adipose lipolysis NASH can lead to more severe forms of liver disease such Steatosis as cirrhosis, hepatocellular carcinoma, liver failure, and De novo O ↑ lipogenesis HO eventually necessitate liver transplantation. Due to this large clinical burden, research efforts have greatly expanded Fatty acids to better understand NAFLD pathogenesis and the mechanisms underlying the transition to NASH.
    [Show full text]
  • Emerging Drug List AMLEXANOX
    Emerging Drug List AMLEXANOX NO. 1 APRIL 2001 Trade Name (Generic): Amlexanox ( Apthera®) Manufacturer: Access Pharmaceuticals, Inc. / Paladin Labs Inc. Indication: For the treatment of aphthous ulcers (canker sores). Current Regulatory Amlexanox paste is currently marketed in the United States under the trademark Status (in Canada Apthasol™ and is also available in Japan in a tablet formulation for the treatment of and abroad): asthma. A Notice of Compliance was received from the Therapeutic Products Programme on December 11th, 2000. Paladin Labs Inc. would be the distributor of this product in Canada and they expect to launch the product early in the year 2001. Description: At this time, the exact mechanism of action by which amlexanox causes accelerated healing of aphthous ulcers is unknown. Amlexanox, an antiallergic agent, is a potent inhibitor of the formation and/or release of inflammatory mediators from cells including neutrophils and mast cells. As soon as a canker sore is discovered, a small amount of paste (i.e., 0.5 cm) is applied four times daily to each ulcer. Treatment is continued until the ulcer is healed. Should no significant healing or pain relief be apparent after 10 days of use, medical or dental advice should be sought. Apthera® is expected to be available as a 5% paste formulation in Canada. Current Treatment: Treating aphthous ulcers can be accomplished via topical and oral interventions. Medications are aimed at reducing secondary infection, controlling pain, reducing the duration of lesion presence, and possibly preventing recurrence. There have been numerous medications studied in the treatment of the lesions, both systemic and topical.
    [Show full text]
  • For Peer Review Only
    BMJ Open BMJ Open: first published as 10.1136/bmjopen-2016-012177 on 30 November 2016. Downloaded from Commonly prescribed drugs associated with cognition: a cross-sectional study in UK Biobank ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2016-012177 Article Type: Research Date Submitted by the Author: 06-Apr-2016 Complete List of Authors: Nevado-Holgado, Alejo; University of Oxford, Psychiatry Kim, Chi-Hun; University of Oxford, Psychiatry Winchester, Laura; University of Oxford, Psychiatry Gallacher, John; University of Oxford, Psychiatry Lovestone, Simon; University of Oxford, Psychiatry <b>Primary Subject Public health Heading</b>: Secondary Subject Heading: Mental health, Pharmacology and therapeutics, Neurology Keywords: PUBLIC HEALTH, MENTAL HEALTH, Cognition, UK biobank http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. For peer review only − http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 16 BMJ Open BMJ Open: first published as 10.1136/bmjopen-2016-012177 on 30 November 2016. Downloaded from 1 2 3 Commonly prescribed drugs associate with cognition: a cross-sectional study 4 in UK Biobank 5 6 7 8 Authors 9 10 Alejo J Nevado-Holgado*, Chi-Hun Kim*, Laura Winchester, John Gallacher, Simon Lovestone 11 12 13 14 15 Address For peer review only 16 17 Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX, UK 18 19 20 21 22 23 Authors’ names and positions 24 25 Alejo J Nevado-Holgado*: Postdoctoral researcher 26 27 Chi-Hun Kim*: Postdoctoral researcher 28 29 Laura Winchester: Postdoctoral researcher 30 31 John Gallacher: Professor 32 33 Simon Lovestone: Professor 34 http://bmjopen.bmj.com/ 35 *These authors contributed equally to this work.
    [Show full text]
  • Supplementary Information
    1 SUPPLEMENTARY INFORMATION 2 ATIQ – further information 3 The Asthma Treatment Intrusiveness Questionnaire (ATIQ) scale was adapted from a scale originally 4 developed by Professor Horne to assess patients’ perceptions of the intrusiveness of antiretroviral 5 therapies (HAART; the HAART intrusiveness scale).1 This scale assesses convenience and the degree 6 to which the regimen is perceived by the patient to interfere with daily living, social life, etc. The 7 HAART intrusiveness scale has been applied to study differential effects of once- vs. twice-daily 8 antiretroviral regimens2 and might be usefully applied to identify patients who are most likely to 9 benefit from once-daily treatments. 10 11 References: 12 1. Newell, A., Mendes da Costa, S. & Horne, R. Assessing the psychological and therapy-related 13 barriers to optimal adherence: an observational study. Presented at the Sixth International 14 congress on Drug Therapy in HIV Infection, Glasgow, UK (2002). 15 2. Cooper, V., Horne, R., Gellaitry, G., Vrijens, B., Lange, A. C., Fisher, M. et al. The impact of once- 16 nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz- 17 based HAART over 48 weeks: the NOCTE study. J Acquir Immune Defic Syndr 53, 369–377 18 (2010). 19 1 20 Supplementary Table S1. Asthma medications, reported by participants at the time of survey Asthma medication n (%) Salbutamol 406 (40.2) Beclometasone 212 (21.0) Salmeterol plus fluticasone 209 (20.7) Salbutamol plus ipratropium 169 (16.7) Formoterol plus budesonide 166
    [Show full text]
  • Metered Dose Inhalers Contents
    COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 23.10.1998 COM( 1998) 603 final COMMUNICATION FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT STRATEGY FOR THE PHASEOU-T OF CFCs IN METERED DOSE INHALERS CONTENTS Chapter 1 Introduction Page 3 Chapter2 Executive Summary Page4 Chapter 3 CFCs and MDis Page 6 Chapter4 Patient Needs Page 9 Chapter 5 Developing Alternatives to CFC-containing MD Is Page 13 Chapter 6 Approval of new products and post-authorisation surveillance Page 18 Chapter 7 Phasing out CFCs Page 25 Chapter 8 Awareness raising Page 34 Chapter 9 Exports of MD Is from the EC Page 38 Chapter 10 CFC production Issues Page 40 Chapter 11 The Essential Use Process -Overview and Timetable Page 43 2 CHAPTER 1 INTRODUCTION 1.1 Decision IX/19 of the Parties to the Montreal Protocol reqmres Parties requesting essential use nominations for chlorofluorocarbons CFCs for metered-dose inhalers (MDis) to present to the Ozone Secretariat an initial national or regional transition strategy if possible by 31 January 1998, and in any case by 31 January 1999. The European Community is a Party to the Montreal Proklc.'t>l, and this document is its transition strategy prepared in accordance with decision IX/19 of the Parties. The European Community believes that a transition strategy is necessary to set out how the transition out of CFCs in MD Is is to be managed such that the CFCs can be phased out as quickly as possible without putting in jeopardy supplies of necessary medicines to patients in need. 1.2 The European Community, on behalf of the Member States, submits a joint request every year to the Parties for the continued use of CFCs to.manufacture MDis.
    [Show full text]